A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital.

Pediatrics

Department of Pediatrics, Sophia Children's Hospital, Erasmus Medical Center Rotterdam (EMCR), Rotterdam, The Netherlands.

Published: November 2001

Background: The treatment of pediatric patients with drugs in hospitals is being impeded by a shortage in the availability of licensed drugs in an appropriate formulation. We have studied the extent of use of drugs that are not licensed for use in children (unlicensed) and drugs that are used outside the terms of the product license (off-label). We conducted this study in a Dutch academic children's hospital.

Methods: In a prospective study of 5 weeks' duration, we reviewed drug prescriptions in a pediatric ward and 3 intensive care units. We classified the prescribed drugs in 3 main categories-licensed, unlicensed, and off-label-and determined the nature of their unlicensed and off-label use.

Results: Two thousand one hundred thirty-nine courses of drugs were administered to 237 patients in 442 patient-days. Of 2139 prescriptions, 725 (34%) were licensed, 1024 (48%) were unlicensed, and 390 (18%) were off-label. In 392 (90%) of 435 patient-days, children received 1 or more courses of an unlicensed or off-label drug prescription in hospital.

Conclusion: With regard to the availability of drugs of proven quality and adequate license for pediatric patients in hospital, dramatic shortcomings exist. As a result, drug legislation originally designed to protect patients and prescribing physicians against unsafe drug use and unjustified claims has turned into an insurmountable threshold to make proper drugs available for a vulnerable minority of patients.

Download full-text PDF

Source
http://dx.doi.org/10.1542/peds.108.5.1089DOI Listing

Publication Analysis

Top Keywords

drugs
9
unlicensed drugs
8
pediatric patients
8
unlicensed off-label
8
unlicensed
6
patients
5
survey off-label
4
off-label unlicensed
4
drugs dutch
4
dutch children's
4

Similar Publications

Repurposing the familiar: Future treatment options against chronic kidney disease.

J Pharm Pharmacol

January 2025

Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani Campus, 333031, Rajasthan, India.

Objectives: Chronic kidney disease (CKD) is a serious health issue with rising morbidity and mortality rates. Despite advances in understanding its pathophysiology, effective therapeutic options are limited, necessitating innovative treatment approaches. Also, current frontline treatments that are available against CKD are not uniformly effective and often come with significant side effects.

View Article and Find Full Text PDF

Ginseng and its processed products are valued as health foods for their nutritional benefits. The traditional forms of processed ginseng include white ginseng, dali ginseng (DLG), red ginseng (RG), and black ginseng (BG). However, the impact of processing on the chemical composition and anti-tumor efficacy of these products is not well understood.

View Article and Find Full Text PDF

This study was intended to provide a novel process that fills a knowledge gap in relation to the enhancement of pulses utilization. The primary goal was to develop an experimental framework for using a high-pressure supercritical fluid extruder (SCFX) as a continuous bioreactor to produce off-flavor reduced and functionally superior pulse flours and protein concentrates in a single step. The current study focused on using SCFX processing to remove off-flavor from pulse flour and protein concentrates, enhancing the quality, acceptability, and marketability of pulse-based products.

View Article and Find Full Text PDF

This study aimed to investigate the potential hypoglycemic mechanism of red ginseng acidic polysaccharides (RGAP) from the perspective of fatty acid (FA) regulation. A high-glucose/high-fat diet in conjunction with streptozotocin administration was employed to establish type 2 diabetes mellitus (T2DM) rat models, and their fecal FAs were detected using the liquid chromatography-mass spectrometry (LC-MS) method. RGAP treatment alleviated the polyphagia, polydipsia, weight loss, and hyperglycemia observed in T2DM rats.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!